62 studies found for:    burzynski
Show Display Options
Download search resultsDownload the search results for:
burzynski (62 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
2 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Condition: Adrenocortical Carcinoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
3 Unknown  Antineoplaston Therapy in Treating Patients With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
4 Unknown  Antineoplaston Therapy in Treating Children With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
5 Unknown  Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
6 Unknown  Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
7 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
8 Unknown  Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
9 Unknown  Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
10 Unknown  Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
11 Unknown  Antineoplaston Therapy in Treating Patients With Refractory or Recurrent Intermediate-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
12 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
13 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
14 Withdrawn Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
15 Terminated Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
16 Completed Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
17 Unknown  Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
18 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
19 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
20 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years